Ribupatide: a China-originated GLP-1/GIP dual agonist's breakout case study in globalization

Over the past decade, incretin drugs have gone through three generational leaps: from GLP-1 mono-agonists (exenatide → liraglutide → semaglutide), to GLP-1/GIP dual agonists (tirzepatide), and on to GLP-1/GIP/GCG triple agonists (mazdutide, retatrutide, etc.). Ribupatide locks onto the middle lane, the most validated and most risk-controllable — dual agonism of the GLP-1 and GIP receptors.

There is clear pharmaceutical-industry logic behind this choice. Lilly's tirzepatide showed in its two big SURPASS and SURMOUNT series that GLP-1 + GIP synergy can push weight loss a step beyond mono-agonists without significantly increasing gastrointestinal adverse reactions. In 2025, tirzepatide's global sales exceeded US$18.4 billion, one of the fastest ramps in pharma history. Locking onto the same mechanism means ribupatide's biological risk has been cleared by predecessors, leaving mainly the engineering question of "can it be done better".

Hengrui's engineering answer has two parts. First, at the structural level, in-house peptide design achieves balanced agonism at the EC50 level, with the GLP-1/GIP agonism ratio tilted slightly toward the GIP side in preclinical models, aiming to reduce nausea and vomiting while preserving weight-loss magnitude. Second, it is developing a modified oral formulation in parallel — ribupatide's most significant differentiation from tirzepatide.

Clinical readouts support both engineering trade-offs. In the China Phase 2 36-week study, the highest-dose arm reduced body weight by 23.6% from baseline, comparable to tirzepatide's 72-week SURMOUNT-1 data in half the time; in Phase 3 (GEMINI-1), the more robust 6 mg dose achieved 19.2% weight loss at 48 weeks; more notably, 26-week Phase 2 data for the oral formulation (NCT06841445) showed 12.1% weight loss with no discontinuations due to gastrointestinal adverse reactions — a safety performance better than early readouts of comparable oral GLP-1 assets in the industry.

In terms of competitive positioning, ribupatide is a typical "fast follow + differentiated improvement" — the same mechanism has been validated by precedent, but it makes claimable differences in formulation mix, safety profile and fit with local Chinese settings. This is not the high-risk, high-reward bet of first-in-class, but a medium-risk route of best-in-region stacked with a dual-formulation moat.

It should be pointed out that ribupatide's "dual formulation" narrative corresponds to different depths of differentiation at different times. In the Chinese market in 2026–2027, the injectable is the main battlefield, and ribupatide's differences from tirzepatide, mazdutide and olatorepatide lie mainly in subtle differences in data curves and pricing strategy; after 2028, if the oral formulation launches as planned, ribupatide will enter the oral niche against Novo Nordisk's oral semaglutide and Lilly's orforglipron — but note that Lilly's orforglipron is a true small molecule with far lower process cost than a modified peptide, so ribupatide's oral tablet may have no structural advantage on COGS and will need better weight loss or better safety to support differentiated pricing. Whether this differentiation holds will depend on the oral Phase 3 readout in 2027.

China is the market with the largest absolute population of obesity and metabolic syndrome in the world, but also one of the major markets with the lowest penetration of weight-loss drugs. Data from the 2025 Report on Nutrition and Chronic Disease Status of Chinese Residents show adult overweight exceeding 50% (about 600 million people) and obesity exceeding 16% (about 240 million), plus about 140 million T2DM patients (IDF 2025) and tens of millions at high risk of MASH — a treatable population on a scale rare in the history of the pharmaceutical industry.

But penetration is badly mismatched with population size. Penetration of GLP-1 drugs in the overweight/obesity indication in China has long been below 1%, with three main blockages: accessibility (the weight-loss version of semaglutide was in short supply for a long time), affordability (monthly self-pay costs long exceeded RMB 1,000), and physician/patient awareness (most primary-care physicians still regard obesity as a lifestyle problem rather than a disease).

2026 is an inflection year for China's GLP-1 market. After inclusion in the NRDL at the start of the year, the monthly cost of Lilly's tirzepatide fell to the RMB 324–551 range, equivalent to a monthly gym pass in a first-tier city; Novo Nordisk cut the price of the weight-loss version of semaglutide by more than 50%; domestic mazdutide (Innovent, approved 2025.6) and ecnoglutide (Sciwind, approved 2026.3) opened domestic innovative substitution; and at the same time, semaglutide generics from at least 10 domestic companies entered Phase 3. The affordability bottleneck for patients is being broken, but the double pressure of product homogeneity and price war is arriving at the same time.

For ribupatide, the key to market opportunity lies in three mismatches:

• Formulation mismatch: all GLP-1 weight-loss drugs currently approved in China are once-weekly injectables, and a multi-formulation choice has not yet formed. Once ribupatide's oral tablet completes Phase 3 and is approved, it will fill the niche of "low-frequency outpatient follow-up + mild-to-moderate obesity + needle-phobic patients".
• Department mismatch: the core battlefields of tirzepatide and semaglutide are endocrinology and weight management clinics; leveraging the channel density of Hengrui's 25,000+ hospitals and 200,000+ retail pharmacies, ribupatide can simultaneously enter new settings such as cardiology (expansion into CV risk reduction), health check-up centers (early intervention for overweight healthy people) and internet hospital DTP (self-medication for mild cases).
• Price positioning mismatch: the COGS disadvantage of a synthetic peptide is a weakness in a price-war environment, but Hengrui has ample experience with the "NRDL value anchor" logic of pricing domestic innovative drugs; drawing on its PD-1 product's strategy of "rapid NRDL inclusion + out-of-hospital DTP volume expansion", it can make the weight-loss drug a mass consumer product rather than a luxury drug.

The China NDA for ribupatide injection was accepted by the NMPA in September 2025; on a standard new drug review timeline, approval within 2026 is the base case. But from NDA to global launch is a continuous run through seven gates, each of which could become a value bottleneck.

Ribupatide is not just a molecule but Hengrui's boldest organizational experiment in a decade. In May 2024, Hengrui bundled ribupatide (HRS9531) with HRS-7535 (an oral small-molecule GLP-1 mono-agonist) and HRS-4729 (a GLP-1/GIP/GCG triple agonist), and granted global rights outside Greater China to the newly formed Kailera Therapeutics, for consideration of US$110 million upfront + up to US$6 billion in milestones + about 9.8% of Kailera's equity held by Hengrui. In April 2026 Kailera listed on Nasdaq, raising US$625 million and jumping 62.5% on its first day; based on first-day market capitalization, the value of Hengrui's stake is close to twice the cash upfront of the deal.

This is one of the landmark cases of the "NewCo model" for Chinese innovative drug companies. It solves three structural problems of internationalization for domestic pharma:

• Governance and cultural mismatch: executing GLP-1 trials overseas requires an operating team familiar with FDA procedures, Western CROs and multinational KOL networks, while the management logic of the domestic headquarters (OBU-oriented, anchored in oncology) is significantly culturally misaligned with global development in metabolism. As an independent company, Kailera hired executives with former Novo Nordisk and Lilly backgrounds, bypassing this friction.
• Capital and risk isolation: a single global Phase 3 trial can cost US$500 million to US$1 billion, plus funding needs for building overseas commercialization, which the balance sheet of a domestic listed company struggles to bear. The NewCo's independent financing (US$400 million Series A + US$600 million Series B + US$625 million IPO, US$1.625 billion in total) isolates R&D capital from the domestic entity, and failure would not drag down the parent's valuation.
• Value discovery and re-pricing: inside Hengrui, ribupatide was seen as "one of the pipeline assets", but as Kailera's core asset the market re-priced it at Nasdaq valuation multiples for metabolic biotechs. Hengrui both keeps Greater China cash flow and shares in the high multiples of overseas capital markets through equity.

But the NewCo model is not perfect. It converts the "rights risk" of overseas failure into "market value risk" on Hengrui's stake — Kailera's share price volatility directly affects Hengrui's financial statements (under the equity method or fair value measurement); it also hands the pace of overseas development from Hengrui's internal decision-making to Kailera's management and board, and the synergy of "Chinese data supporting the overseas label in reverse" requires ongoing governance coordination. It is worth comparing several other Chinese pharma cases that went global via NewCo paths: Innovent–Fortvita, Harbour BioMed–Nona Biosciences and Akeso–Summit, whose common feature is that at the deal design stage they all specified a hybrid structure of "parent holds 10%–20% + milestones + equity/license-back clauses", upgrading a plain license-out into "rights bundling". What distinguishes the Kailera case is that its asset bundle is the heaviest (three assets packaged), its upfront ratio relatively low (US$110 million against US$6 billion in milestones), and the domestic parent's voice more prominent — in essence trading a discounted upfront for greater room for overseas equity re-pricing.

Whether this organizational design succeeds will ultimately come down to three measures: whether the overseas Phase 3 reads out on time and with quality, whether an overseas commercial team can be built in 2028–2029, and whether Kailera's share price can stay stable after the lock-up period (usually one year). Losing any one of these would turn the "NewCo premium" into a "NewCo discount". For Hengrui, ribupatide is both an offensive and a touchstone — success would prove that Chinese innovative drug globalization has a replicable methodology; failure could trigger a market re-assessment of the whole NewCo model.

From Hengrui's overall strategy, ribupatide's role goes beyond the single product: it is the key vehicle for Hengrui's transformation from "oncology dominance" to multi-curve growth in "oncology + metabolism + autoimmunity"; it is the flagship product of its newly formed BBU (biopharma business unit); and it is the showcase project of its "innovation + internationalization" dual-engine strategy. In 2025 Hengrui's R&D investment was RMB 8.724 billion, innovative drugs accounted for 58.34% of revenue, and non-oncology product revenue grew 73.36% year on year — whether ribupatide's commercialization succeeds will directly determine the slope of this second growth curve.

Compared on "percentage weight loss" alone, the differences between ribupatide and tirzepatide, mazdutide and olatorepatide are limited — all in the 18–23% range, making it hard for clinicians to form a strong preference from numbers alone. What really determines ribupatide's commercial value is whether it can reframe its narrative from "single-indication weight-loss drug" to "foundation therapy for the whole metabolic syndrome".

This reframing has three potential axes:

Axis one: combined T2DM management. The Phase 3 for ribupatide's T2DM indication is expected to read out in 2026. More than 60% of China's T2DM population (about 140 million) also has obesity, while GLP-1 penetration in T2DM treatment is below 5%. If ribupatide can show both significant HbA1c reduction and significant weight loss in T2DM, it will become endocrinology's "one drug, two functions" first choice, and open commercial space under NRDL payment far beyond the single weight-loss indication.

Axis two: MASH and hepatic metabolism expansion. Tirzepatide's SYNERGY-NASH study has already shown the potential of GLP-1/GIP dual agonism in MASH. China has a huge MASH patient base but currently no approved therapy (Rezdiffra has limited penetration because MASH diagnosis requires a liver biopsy). If ribupatide starts a Phase 3 in MASH in 2027–2028 targeting patients with F2/F3 liver fibrosis, it will enter a niche with no price war and high unmet need.

Axis three: cardiovascular and renal outcome studies. Semaglutide's SELECT and FLOW trials have shown that GLP-1 drugs can reduce cardiovascular events and slow CKD progression, and this "hard endpoint" value is at the core of payers' willingness to pay. If ribupatide can start CVOT and CKD outcome studies with support from Chinese cardiology and nephrology KOLs, it can reshape its label from "weight-loss drug" to "foundation therapy for metabolic syndrome", entering the same clinical positioning tier as tirzepatide and semaglutide.

The access strategy for GLP-1 weight-loss drugs in China is rewriting the rules in 2026. Tirzepatide's successful NRDL inclusion in January set the precedent of "an innovative weight-loss drug entering the payment system via NRDL negotiation"; at the same time, the National Healthcare Security Administration's access conditions for weight-loss indications (BMI thresholds, comorbidity requirements, periodic reassessment) are becoming clearer. If ribupatide wants to enter the NRDL within 2 years of approval, it needs to do three things:

1. Economic evidence first. China's health economic evaluation standards for GLP-1 drugs have expanded from "cost-utility" to "reduction of long-term medical burden". Ribupatide needs to launch a budget impact analysis (BIA) and cost-utility analysis (CUA) for the Chinese population in parallel at the NDA stage, using local real-world evidence to demonstrate its differentiated economic value relative to tirzepatide and mazdutide — for example, improved adherence from dual formulations and reduced long-term resource use from safety advantages.

2. Rapid accumulation of real-world evidence. The first 12 months after approval in 2026 are the golden period for accumulating real-world evidence (RWE). A dedicated RWE team should be built covering 30 core tertiary hospitals, systematically collecting key real-world endpoints (weight maintenance, adherence, discontinuation rates, improvement in comorbidities) as the core argument for NRDL negotiations in 2027–2028.

3. Linking out-of-hospital channels and internet hospitals. The channel density of Hengrui's 25,000+ hospitals and 200,000+ retail pharmacies is a key asset, but the particular nature of the weight-loss market means out-of-hospital channels (DTP pharmacies, internet hospitals, JD Health/Alibaba Health) will carry most of the increment. Ribupatide needs to launch, at approval, a full patient pathway of "first diagnosis in hospital + out-of-hospital refills + internet follow-up", differentiating from tirzepatide's traditional hospital-centric battlefield.

Over the next 48 months, the questions ribupatide has to answer are: can it achieve annual sales of RMB 5 billion+ within two years of launch in China? Can Kailera's global Phase 3 read out successfully and open overseas cash flow? Can it complete next-generation reserves before the era of GLP-1/GIP/GCG triple agonists arrives? The answers to these three questions will determine whether the Hengrui–Kailera NewCo experiment becomes the model for Chinese innovative drugs going global, or another story drowned in international competition.